



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/619,268  
Applicant: Charles Q. Meng.  
Filed: July 14, 2003  
TC/A.AU.: Unassigned  
Examiner: Unassigned

Confirmation No.: 6328

Docket No.: 04676.105081 ATH 123US  
Customer No.: 20786  
Title: Novel Salt Forms of Poorly Soluble Probucol Esters and Ethers

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe any fees are due because this paper is submitted before the mailing of a first Office action on the merits of the application, as under 37 C.F.R. § 1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

*Madeline I. Johnston*  
Madeline I. Johnston  
Reg. No. 36,174

Date: January 30, 2004  
King & Spalding, LLP  
191 Peachtree Street, N.E., Atlanta, GA 30303  
Office: (404)572-4600/ Fax: 404-572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 30, 2004.

*Tisha Hardrick*  
Tisha Hardrick

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
Application Number				10/619,268	
Filing Date				July 14, 2003	
First Named Inventor				Charles Q. Meng	
Group Art Unit				Unassigned	
Examiner Name				Unassigned	
Attorney Docket Number				04676.105081 ATH 123US	
Sheet	1	of	2		

3389630\_1

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	4,522,811		Eppstein <i>et al.</i>	06-11-1995	
	AB	4,954,514		Kita <i>et al.</i>	09-04-1990	
	AC	5,155,250		Parker <i>et al.</i>	10-13-1992	
	AD	5,262,439		Parthasarathy	11-16-1993	
	AE	5,608,095		Parker <i>et al.</i>	03-04-1997	
	AF	6,121,319		Somers	09-19-2000	
	AG	6,147,250		Somers	11-14-2000	
	AH	2001/0029660	A1	Johnson	10-18-2001	
	AI	2001/0032014	A1	Yang <i>et al.</i>	10-18-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
	AJ	EP	0,348,203 ✓	A1	Shionogi & Co.	12-27-1989		
	AK	EP	0,405,788 ✓	A2	Shionogi & Co.	01-02-1991		
	AL	FR	2130975 ✓		Aries	11-10-1972		
	AM	FR	2133024 ✓		Aries	11-24-1972		
	AN	FR	2134810 ✓		Aries	12-08-1972		
	AO	FR	2140769 ✓		Aries	01-19-1973		
	AP	FR	2140771 ✓		Aries	01-19-1973		
	AQ	FR	2168137 ✓		Dynachim	08-31-1973		Y
	AR	WO	95/15760 ✓		Merrell Dow Pharmaceuticals	06-15-1995		
	AS	WO	01/70757 ✓	A2	Atherogenics	09-27-2001		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/619,268
				Filing Date	July 14, 2003
				First Named Inventor	Charles Q. Meng
				Group Art Unit	Unassigned
Sheet	2	of	2	Attorney Docket Number	04676.105081 ATH 123

3389630\_1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/	BA	BROWN, L., <i>et al.</i> , "Transdermal Delivery of Drugs," <i>Annual Review of Medicine</i> , 39:221-229 (1988).	
/	BB	KAPLAN, N.M., "Chapter 26: Systemic hypertension: mechanisms and diagnosis," in <i>Heart Disease</i> , 5 <sup>th</sup> ed., Braunwald, E., Ed., W.B. Saunders & Co., Philadelphia, 1997, pp. 807-823.	
/	BC	MENG, C.Q., <i>et al.</i> , "Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis," <i>Bioorganic &amp; Med. Chem. Ltrs.</i> , 12(18):2545-2548 (2002).	
/	BD	SUNDELL, <i>et al.</i> , "AGIX-4207: A novel antioxidant and anti-inflammatory compound inhibits progression of collagen II arthritis in the rat," <i>FASEB Journal</i> , 16(4):A182 (April 20-24, 2002), Annual Meeting of the Professional Research Scientists on Experimental Biology, ISSN 0892-6638.	

3389630\_1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.